Clinical Rheumatology

, Volume 37, Issue 5, pp 1351–1358 | Cite as

Assessment of cardiovascular risk profile based on measurement of tophus volume in patients with gout

  • Kyung-Ann Lee
  • Se-Ri Ryu
  • Seong-Jun Park
  • Hae-Rim Kim
  • Sang-Heon Lee
Original Article
First Online:
Received:
Accepted:

Abstract

Hyperuricemia and gout are associated with increased risk of cardiovascular disease and metabolic syndrome. The aim of this study was to evaluate the correlation of total tophus volumes, measured using dual-energy computed tomography, with cardiovascular risk and the presence of metabolic syndrome. Dual-energy computed tomography datasets from 91 patients with a diagnosis of gout were analyzed retrospectively. Patients who received urate lowering therapy were excluded to avoid the effect on tophus volume. The total volumes of tophaceous deposition were quantified using automated volume assessment software. The 10-year cardiovascular risk using the Framingham Risk Score and metabolic syndrome based on the Third Adult Treatment Panel criteria were estimated. Fifty-five and 36 patients with positive and negative dual-energy computed tomography results, respectively, were assessed. Patients with positive dual-energy computed tomography results showed significantly higher systolic blood pressure, diastolic blood pressure, fasting glucose, and higher prevalence of chronic kidney disease, compared with those with negative dual-energy computed tomography results. The total tophus volumes were significantly correlated with the Framingham Risk Score, and the number of metabolic syndrome components (r = 0.22 and p = 0.036 and r = 0.373 and p < 0.001, respectively). The total tophus volume was one of the independent prognostic factors for the Framingham Risk Score in a multivariate analysis. This study showed the correlation of total tophus volumes with cardiovascular risk and metabolic syndrome-related comorbidities. A high urate burden could affect unfavorable cardiovascular profiles.

Keywords

Cardiovascular diseases Dual-energy computed tomography Gout Hyperuricemia Metabolic syndrome 
This is a preview of subscription content, log in to check access.

Notes

Funding information

This research was supported by the Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2017R1A2B4006015).

Compliance with ethical standards

This study was conducted in compliance with the Helsinki Declaration to protect human subjects and was approved by the Institutional Review Board for Human Research, Konkuk University Medical Center (KUH Number 1010845).

Disclosures

None.

Supplementary material

10067_2017_3963_MOESM1_ESM.docx (20 kb)
Supplementary Table 1 (DOCX 20.1 kb)

References

  1. 1.
    Martillo MA, Nazzal L, Crittenden DB (2014) The crystallization of monosodium urate. Curr Rheumatol Rep 16(2):400.  https://doi.org/10.1007/s11926-013-0400-9 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T, Hisatome I (2017) Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol 231:137–142.  https://doi.org/10.1016/j.ijcard.2016.11.268 CrossRefPubMedGoogle Scholar
  3. 3.
    Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramatsu T, Takefuji S, Hotta Y, Kondo T, Murohara T, Toyoshima H, Tamakoshi K (2009) Uric acid and left ventricular hypertrophy in Japanese men. Circ J 73(4):667–672.  https://doi.org/10.1253/circj.CJ-08-0626 CrossRefPubMedGoogle Scholar
  4. 4.
    Mason JC, Libby P (2015) Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. European Heart J 36(8):482–489.  https://doi.org/10.1093/eurheartj/ehu403 CrossRefGoogle Scholar
  5. 5.
    Janssens HJ, Arts PG, Schalk BW, Biermans MC (2017) Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: a primary care retrospective cohort study. Joint, Bone, Spine: Revue du Rhumatisme 84(1):59–64.  https://doi.org/10.1016/j.jbspin.2015.12.003 CrossRefGoogle Scholar
  6. 6.
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331.  https://doi.org/10.1136/ard.2009.113696 CrossRefPubMedGoogle Scholar
  7. 7.
    Omoumi P, Verdun FR, Guggenberger R, Andreisek G, Becce F (2015) Dual-energy CT: basic principles, technical approaches, and applications in musculoskeletal imaging (part 2). Semin Musculoskelet Radiol 19(5):438–445.  https://doi.org/10.1055/s-0035-1569252 CrossRefPubMedGoogle Scholar
  8. 8.
    Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N et al (2009) Outcome domains for studies of acute and chronic gout. J Rheumatol 36(10):2342–2345.  https://doi.org/10.3899/jrheum.090370 CrossRefPubMedGoogle Scholar
  9. 9.
    Modjinou DV, Krasnokutsky S, Gyftopoulos S, Pike VC, Karis E, Keenan RT, Lee K, Crittenden DB, Samuels J, Pillinger MH (2017) Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. Clin Rheumatol 36(9):2101–2107.  https://doi.org/10.1007/s10067-017-3729-z CrossRefPubMedGoogle Scholar
  10. 10.
    Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A et al (2015) Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD open 1:e000075CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847.  https://doi.org/10.1161/01.CIR.97.18.1837 CrossRefPubMedGoogle Scholar
  12. 12.
    D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753.  https://doi.org/10.1161/CIRCULATIONAHA.107.699579 CrossRefPubMedGoogle Scholar
  13. 13.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752.  https://doi.org/10.1161/CIRCULATIONAHA.105.169404 CrossRefPubMedGoogle Scholar
  14. 14.
    Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung S, Kim CG, Choe JY, Lee SW, Chung WT, Song GG (2005) The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 20(6):1029–1033.  https://doi.org/10.3346/jkms.2005.20.6.1029 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & rheumatology (Hoboken, NJ) 2015;67 10: 2557-68Google Scholar
  16. 16.
    Panel TRotNCEPNE. Detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of HealthGoogle Scholar
  17. 17.
    Thomas C, Patschan O, Ketelsen D, Tsiflikas I, Reimann A, Brodoefel H, Buchgeister M, Nagele U, Stenzl A, Claussen C, Kopp A, Heuschmid M, Schlemmer HP (2009) Dual-energy CT for the characterization of urinary calculi: in vitro and in vivo evaluation of a low-dose scanning protocol. Eur Radiol 19(6):1553–1559.  https://doi.org/10.1007/s00330-009-1300-2 CrossRefPubMedGoogle Scholar
  18. 18.
    Baer AN, Kurano T, Thakur UJ, Thawait GK, Fuld MK, Maynard JW, McAdams-DeMarco M, Fishman EK, Carrino JA (2016) Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout. BMC Musculoskelet Disord 17(1):91.  https://doi.org/10.1186/s12891-016-0943-9 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Full LE, Ruisanchez C, Monaco C (2009) The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 11(2):217.  https://doi.org/10.1186/ar2631
  20. 20.
    Kienhorst LB, van Lochem E, Kievit W, Dalbeth N, Merriman ME, Phipps-Green A et al (2015) Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease. Arthritis Rheumatol 67(12):3303–3313.  https://doi.org/10.1002/art.39318 CrossRefPubMedGoogle Scholar
  21. 21.
    Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241.  https://doi.org/10.1038/nature04516 CrossRefPubMedGoogle Scholar
  22. 22.
    Snow MH, Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17(3):234–241PubMedGoogle Scholar
  23. 23.
    Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN (2008) Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 27(8):967–978.  https://doi.org/10.1080/15257770802257952 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN (2009) Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 28(2):118–149.  https://doi.org/10.1080/15257770902736400 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67(5):1739–1742.  https://doi.org/10.1111/j.1523-1755.2005.00273.x CrossRefPubMedGoogle Scholar
  26. 26.
    Gaffo AL, Jacobs DR Jr, Sijtsma F, Lewis CE, Mikuls TR, Saag KG (2013) Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 72(8):1321–1327.  https://doi.org/10.1136/annrheumdis-2012-201916 CrossRefPubMedGoogle Scholar
  27. 27.
    Sattui SE, Singh JA, Gaffo AL (2014) Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin N Am 40(2):251–278.  https://doi.org/10.1016/j.rdc.2014.01.005 CrossRefGoogle Scholar
  28. 28.
    Mankovsky B, Kurashvili R, Sadikot S (2010) Is serum uric acid a risk factor for atherosclerotic cardiovascular disease?: a review of the clinical evidence. Part 1. Diabetes Metabolic Syndrome: Clinical Res Rev 4(3):176–84–176184.  https://doi.org/10.1016/j.dsx.2010.07.010 CrossRefGoogle Scholar
  29. 29.
    Feig DI (2012) The role of uric acid in the pathogenesis of hypertension in the young. Journal Clinical Hypertension 14(6):346–352.  https://doi.org/10.1111/j.1751-7176.2012.00662.x CrossRefGoogle Scholar
  30. 30.
    Pascart T, Grandjean A, Norberciak L, Ducoulombier V, Motte M, Luraschi H, Vandecandelaere M, Godart C, Houvenagel E, Namane N, Budzik JF (2017) Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. Arthritis Res Ther 19(1):171.  https://doi.org/10.1186/s13075-017-1381-2 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112(20):3066–3072.  https://doi.org/10.1161/CIRCULATIONAHA.105.539528 CrossRefPubMedGoogle Scholar
  32. 32.
    Gonzalez-Senac NM, Bailen R, Torres RJ, de Miguel E, Puig JG (2014) Metabolic syndrome in primary gout. Nucleosides Nucleotides Nucleic Acids 33(4–6):185–191.  https://doi.org/10.1080/15257770.2013.853785 CrossRefPubMedGoogle Scholar
  33. 33.
    Zhu Y, Zhang Y, Choi HK (2010) The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology 49(12):2391–2399.  https://doi.org/10.1093/rheumatology/keq256 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165(7):742–748.  https://doi.org/10.1001/archinte.165.7.742 CrossRefPubMedGoogle Scholar
  35. 35.
    Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, Lanaspa MA, Nakagawa T, Johnson RJ (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. European J Internal Medicine 29:3–8.  https://doi.org/10.1016/j.ejim.2015.11.026 CrossRefGoogle Scholar
  36. 36.
    Feig DI, Kang D-H, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359(17):1811–1821.  https://doi.org/10.1056/NEJMra0800885 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Johnson RJ, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6):1183–1190.  https://doi.org/10.1161/01.HYP.0000069700.62727.C5 CrossRefPubMedGoogle Scholar
  38. 38.
    Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393.  https://doi.org/10.2215/CJN.01580210 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Yu S, Yang H, Guo X, Zheng L, Sun Y (2015) Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China. Gynecol Endocrinol 31(9):736–741.  https://doi.org/10.3109/09513590.2015.1056730 CrossRefPubMedGoogle Scholar
  40. 40.
    Lin JC, Lin CL, Chen MC, Chang PJ, Chang ST, Chung CM, et al (2015) Gout, not hyperuricemia alone, impairs left ventricular diastolic function. Arthritis Res Ther 17:323.  https://doi.org/10.1186/s13075-015-0842-8

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Kyung-Ann Lee
    • 1
  • Se-Ri Ryu
    • 2
  • Seong-Jun Park
    • 2
  • Hae-Rim Kim
    • 1
  • Sang-Heon Lee
    • 1
    • 2
  1. 1.Department of Internal MedicineKonkuk University Medical CenterSeoulSouth Korea
  2. 2.Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical CenterKonkuk University School of MedicineSeoulSouth Korea

Personalised recommendations